Literature DB >> 16847467

Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity.

S Fuselli1, R H Gilman, S J Chanock, S L Bonatto, G De Stefano, C A Evans, D Labuda, D Luiselli, F M Salzano, G Soto, G Vallejo, A Sajantila, D Pettener, E Tarazona-Santos.   

Abstract

N-acetyltransferase 2 (NAT2), an important enzyme in clinical pharmacology, metabolizes antibiotics such as isoniazid and sulfamethoxazole, and catalyzes the transformation of aromatic and heterocyclic amines from the environment and diet into carcinogenic intermediates. Polymorphisms in NAT2 account for variability in the acetylator phenotype and the pharmacokinetics of metabolized drugs. Native Americans, settled in rural areas and large cities of Latin America, are under-represented in pharmacogenetics studies; therefore, we sequenced the coding region of NAT2 in 456 chromosomes from 13 populations from the Americas, and two from Siberia, detecting nine substitutions and 11 haplotypes. Variants *4 (37%), *5B (23%) and *7B (24%) showed high frequencies. Average frequencies of fast, intermediate and slow acetylators across Native Americans were 18, 56 and 25%, respectively. NAT2 intra-population genetic diversity for Native Americans is higher than East Asians and similar to the rest of the world, and NAT2 variants are homogeneously distributed across native populations of the continent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847467      PMCID: PMC3099416          DOI: 10.1038/sj.tpj.6500407

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  58 in total

1.  Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype.

Authors:  W M O'Neil; R K Drobitch; R D MacArthur; M J Farrough; M A Doll; A J Fretland; D W Hein; L R Crane; C K Svensson
Journal:  Pharmacogenetics       Date:  2000-03

2.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

3.  A human genome diversity cell line panel.

Authors:  Howard M Cann; Claudia de Toma; Lucien Cazes; Marie-Fernande Legrand; Valerie Morel; Laurence Piouffre; Julia Bodmer; Walter F Bodmer; Batsheva Bonne-Tamir; Anne Cambon-Thomsen; Zhu Chen; J Chu; Carlo Carcassi; Licinio Contu; Ruofu Du; Laurent Excoffier; G B Ferrara; Jonathan S Friedlaender; Helena Groot; David Gurwitz; Trefor Jenkins; Rene J Herrera; Xiaoyi Huang; Judith Kidd; Kenneth K Kidd; Andre Langaney; Alice A Lin; S Qasim Mehdi; Peter Parham; Alberto Piazza; Maria Pia Pistillo; Yaping Qian; Qunfang Shu; Jiujin Xu; S Zhu; James L Weber; Henry T Greely; Marcus W Feldman; Gilles Thomas; Jean Dausset; L Luca Cavalli-Sforza
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

4.  On the number of segregating sites in genetical models without recombination.

Authors:  G A Watterson
Journal:  Theor Popul Biol       Date:  1975-04       Impact factor: 1.570

5.  Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa.

Authors:  Sohini Ramachandran; Omkar Deshpande; Charles C Roseman; Noah A Rosenberg; Marcus W Feldman; L Luca Cavalli-Sforza
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-21       Impact factor: 11.205

6.  Human acetyltransferase polymorphisms.

Authors:  D M Grant; N C Hughes; S A Janezic; G H Goodfellow; H J Chen; A Gaedigk; V L Yu; R Grewal
Journal:  Mutat Res       Date:  1997-05-12       Impact factor: 2.433

7.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism.

Authors:  F Tajima
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

8.  Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene.

Authors:  H J Lin; C Y Han; B K Lin; S Hardy
Journal:  Pharmacogenetics       Date:  1994-06

9.  Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of point mutation 857A, as found in allele S3/M3.

Authors:  T D Arias; L F Jorge; E U Griese; T Inaba; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1993-12

Review 10.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.

Authors:  David W Hein
Journal:  Mutat Res       Date:  2002-09-30       Impact factor: 2.433

View more
  19 in total

1.  Phred-Phrap package to analyses tools: a pipeline to facilitate population genetics re-sequencing studies.

Authors:  Moara Machado; Wagner Cs Magalhães; Allan Sene; Bruno Araújo; Alessandra C Faria-Campos; Stephen J Chanock; Leandro Scott; Guilherme Oliveira; Eduardo Tarazona-Santos; Maira R Rodrigues
Journal:  Investig Genet       Date:  2011-02-01

2.  Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

Authors:  Simbarashe P Zvada; Paolo Denti; Peter R Donald; H Simon Schaaf; Stephanie Thee; James A Seddon; Heiner I Seifart; Peter J Smith; Helen M McIlleron; Ulrika S H Simonsson
Journal:  J Antimicrob Chemother       Date:  2014-01-31       Impact factor: 5.790

3.  Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations.

Authors:  Holly M Mortensen; Alain Froment; Godfrey Lema; Jean-Marie Bodo; Muntaser Ibrahim; Thomas B Nyambo; Sabah A Omar; Sarah A Tishkoff
Journal:  Pharmacogenomics       Date:  2011-10-13       Impact factor: 2.533

4.  Human loci involved in drug biotransformation: worldwide genetic variation, population structure, and pharmacogenetic implications.

Authors:  Pierpaolo Maisano Delser; Silvia Fuselli
Journal:  Hum Genet       Date:  2013-01-26       Impact factor: 4.132

5.  Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data.

Authors:  Audrey Sabbagh; Pierre Darlu; Michel Vidaud
Journal:  BMC Med Genet       Date:  2009-12-31       Impact factor: 2.103

6.  NAT2 gene diversity and its evolutionary trajectory in the Americas.

Authors:  R Bisso-Machado; V Ramallo; V R Paixão-Côrtes; V Acuña-Alonzo; D A Demarchi; J R S Sandoval; A A S Granara; F M Salzano; T Hünemeier; M C Bortolini
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

7.  Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey.

Authors:  Audrey Sabbagh; Pierre Darlu; Brigitte Crouau-Roy; Estella S Poloni
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

8.  Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations.

Authors:  Jhimmy Talbot; Luiz Alexandre V Magno; Cinthia V N Santana; Sandra M B Sousa; Paulo R S Melo; Ronan X Correa; Giuliano Di Pietro; Fabrício Rios-Santos
Journal:  BMC Genet       Date:  2010-10-05       Impact factor: 2.797

9.  Rapid birth-and-death evolution of the xenobiotic metabolizing NAT gene family in vertebrates with evidence of adaptive selection.

Authors:  Audrey Sabbagh; Julie Marin; Charlotte Veyssière; Emilie Lecompte; Sotiria Boukouvala; Estella S Poloni; Pierre Darlu; Brigitte Crouau-Roy
Journal:  BMC Evol Biol       Date:  2013-03-07       Impact factor: 3.260

10.  Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history.

Authors:  Audrey Sabbagh; André Langaney; Pierre Darlu; Nathalie Gérard; Rajagopal Krishnamoorthy; Estella S Poloni
Journal:  BMC Genet       Date:  2008-02-27       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.